Alectinib-Induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma: Case Report and Literature Review  

作　　者：Chai Young Lee Yon Ju Ryu Chai Young Lee;Yon Ju Ryu(Division of Pulmonary and Critical Care Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea)

机构地区：[1]Division of Pulmonary and Critical Care Medicine, College of Medicine, Ewha Womans University, Seoul, Republic of Korea

出　　处：《Case Reports in Clinical Medicine》2024年第8期321-327,共7页临床医学病理报告（英文）

摘　　要：Alectinib is a selective Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor used as standard therapy for ALK-rearranged lung adenocarcinoma. Hemolytic anemia is considered a rare but significant adverse event of alectinib. Here, we report the case of a 78-year-old female with advanced ALK rearrangement-positive lung adenocarcinoma who developed grade 4 drug-induced hemolytic anemia after receiving alectinib as first-line therapy. We discontinued alectinib treatment and switched to brigatinib. As a result, anemia improved without recurrence of lung adenocarcinoma over one year.Alectinib is a selective Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitor used as standard therapy for ALK-rearranged lung adenocarcinoma. Hemolytic anemia is considered a rare but significant adverse event of alectinib. Here, we report the case of a 78-year-old female with advanced ALK rearrangement-positive lung adenocarcinoma who developed grade 4 drug-induced hemolytic anemia after receiving alectinib as first-line therapy. We discontinued alectinib treatment and switched to brigatinib. As a result, anemia improved without recurrence of lung adenocarcinoma over one year.

关 键 词：Non-Small Cell Lung Cancer Alectinib Brigatinib Hemolytic Anemia Drug-Induced Hemolytic Anemia 

分 类 号：R73[医药卫生—肿瘤]